BR112014009851A2 - moduladores de receptor de nmda e usos dos mesmos - Google Patents

moduladores de receptor de nmda e usos dos mesmos

Info

Publication number
BR112014009851A2
BR112014009851A2 BR112014009851A BR112014009851A BR112014009851A2 BR 112014009851 A2 BR112014009851 A2 BR 112014009851A2 BR 112014009851 A BR112014009851 A BR 112014009851A BR 112014009851 A BR112014009851 A BR 112014009851A BR 112014009851 A2 BR112014009851 A2 BR 112014009851A2
Authority
BR
Brazil
Prior art keywords
compounds
nmda receptor
disclosed
receptor modulators
formulations
Prior art date
Application number
BR112014009851A
Other languages
English (en)
Other versions
BR112014009851A8 (pt
Inventor
M Khan Amin
Moskal Joseph
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of BR112014009851A2 publication Critical patent/BR112014009851A2/pt
Publication of BR112014009851A8 publication Critical patent/BR112014009851A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

abstract disclosed are compounds having enhanced potency in the modulation of nmda receptor activity. such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. ------------------------------------------------------------------------------------------------------------ tradução do resumo resumo patente de invenção: "moduladores de receptor de nmda e usos dos mesmos". são divulgados compostos tendo potência intensificada na modulação da atividade do receptor de nmda. tais compostos são contemplados para uso para tratar doenças e distúrbios, tal como a-prendizagem, atividades cognitivas e analgesia, particularmente, aliviar e/ou reduzir dor neuropática. formulações disponíveis oralmente e ou-tras formas de distribuição farmaceuticamente aceitáveis dos compos-tos, incluindo formulações intravenosas, são também divulgadas.
BR112014009851A 2011-10-24 2012-10-24 moduladores de receptor de nmda e usos dos mesmos BR112014009851A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550782P 2011-10-24 2011-10-24
PCT/US2012/061696 WO2013063120A2 (en) 2011-10-24 2012-10-24 Nmda receptor modulators and uses thereof

Publications (2)

Publication Number Publication Date
BR112014009851A2 true BR112014009851A2 (pt) 2017-04-18
BR112014009851A8 BR112014009851A8 (pt) 2021-06-08

Family

ID=48168770

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009851A BR112014009851A8 (pt) 2011-10-24 2012-10-24 moduladores de receptor de nmda e usos dos mesmos

Country Status (13)

Country Link
US (6) US8673843B2 (pt)
EP (1) EP2771021B1 (pt)
JP (1) JP6210993B2 (pt)
KR (2) KR101692275B1 (pt)
CN (2) CN104321071A (pt)
AU (3) AU2012328927B2 (pt)
BR (1) BR112014009851A8 (pt)
CA (1) CA2853364C (pt)
ES (1) ES2703904T3 (pt)
HK (1) HK1206616A1 (pt)
RU (1) RU2621049C2 (pt)
SG (1) SG11201401776WA (pt)
WO (1) WO2013063120A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
CN102933226A (zh) 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
CN105408336B (zh) 2013-01-29 2018-06-26 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EP2951186B1 (en) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
SG11201505934XA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
JP6255082B2 (ja) 2013-03-13 2017-12-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイドおよびその使用方法
CN104109189B (zh) * 2013-04-18 2019-05-10 中国人民解放军军事医学科学院毒物药物研究所 Thr-Pro-Pro-Thr四肽的液相合成方法
CN105764522A (zh) * 2013-10-28 2016-07-13 诺雷克斯股份有限公司 Nmda受体调节剂及其前药、盐和用途
EP3157528B1 (en) 2014-06-18 2023-09-13 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3171941B1 (en) * 2014-07-24 2021-03-24 Naurex Inc. N-methyl-d-aspartate receptor modulators and methods of making and using same
KR20170065637A (ko) * 2014-10-07 2017-06-13 세이지 테라퓨틱스, 인크. 신경활성 화합물 및 그의 사용 방법
KR20180026742A (ko) 2015-07-06 2018-03-13 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP2018519351A (ja) 2015-07-06 2018-07-19 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
KR20180102052A (ko) * 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
BR112018070123A2 (pt) 2016-04-01 2019-02-05 Sage Therapeutics Inc oxiesterós e métodos de uso dos mesmos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
LT3481846T (lt) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
WO2018026763A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
CN115181153A (zh) 2016-10-18 2022-10-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
CN108148113A (zh) * 2016-12-06 2018-06-12 深圳先进技术研究院 一种nmda受体调控剂四肽衍生物的固相合成方法
CN107474107B (zh) * 2017-05-18 2023-01-17 江苏恩华药业股份有限公司 Glyx-13的制备方法及用于制备glyx-13的化合物
FR3067028B1 (fr) * 2017-06-06 2019-07-12 Adpuerivitam Modulateurs de recepteurs nmda, compositions les comprenant et utilisation de ces composes dans le traitement de maladies impliquant le systeme nerveux central
US20190031715A1 (en) * 2017-07-28 2019-01-31 Naurex, INC Process and intermediates for synthesis of peptide compounds
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
CN110003309B (zh) * 2019-04-09 2021-09-10 北京广为医药科技有限公司 调节nmda受体活性的化合物、其药物组合物及用途

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683221A (en) * 1986-01-09 1987-07-28 Scripps Clinic And Research Foundation Lymphocyte-activating polypeptides
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
CA2058975C (en) 1990-10-30 2000-06-06 Shuichi Kasai Antiinflammatory gel preparation
JP3318622B2 (ja) * 1992-05-27 2002-08-26 独立行政法人産業技術総合研究所 プロリルエンドペプチダーゼ阻害剤
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
WO1997046578A1 (en) 1996-06-07 1997-12-11 Zeneca Limited Peptide derivatives
AU3972797A (en) 1996-08-02 1998-02-25 Zymogenetics Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
US6897028B1 (en) * 1997-07-07 2005-05-24 Florida State University Identification of molecular targets
JP2003524364A (ja) * 1997-07-07 2003-08-19 フロリダ ステート ユニバーシティ 分子ターゲットの同定
AU1585999A (en) 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
US6902886B1 (en) * 1998-11-06 2005-06-07 The Research Foundation Of State University Of New York Genetic assay for protein nuclear transport
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU1922301A (en) 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
US6521414B2 (en) 2000-02-01 2003-02-18 Agy Therapeutics, Inc. Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1
WO2001096606A2 (en) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
EP1296999A2 (en) 2000-06-22 2003-04-02 NYXIS NeuroTherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
AU2002236608A1 (en) 2000-12-14 2002-06-24 Nyxis Neurotherapies, Inc. High throughput assay to detect inhibitors of the map kinase pathway
AU2002248553A1 (en) 2001-03-07 2002-09-24 Cognetix, Inc Linear y-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
CA2449168A1 (en) * 2001-05-31 2002-12-05 The Trustees Of Princeton University Iap binding peptides and assays for identifying compounds that bind iap
WO2003010540A1 (en) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7544478B2 (en) 2003-08-08 2009-06-09 The Burnham Institute Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors
WO2005020973A2 (en) 2003-08-29 2005-03-10 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
EP1945691A2 (en) 2005-08-26 2008-07-23 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2008033464A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101317844B (zh) * 2007-06-08 2010-11-17 章劲夫 化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
CA2732091A1 (en) 2008-08-07 2010-02-11 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
CN102186883B (zh) * 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
TW201028171A (en) * 2008-12-15 2010-08-01 Calpis Co Ltd Peptides for inhibiting skin aging
US20120178695A1 (en) 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
PL2985032T3 (pl) 2009-10-05 2019-07-31 Northwestern University Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
CN102933226A (zh) 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
KR20140043078A (ko) 2011-04-27 2014-04-08 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
US8795919B2 (en) 2011-11-29 2014-08-05 Societe BIC & Sanyo Electric Co., Ltd. Fuel cell layer

Also Published As

Publication number Publication date
US8673843B2 (en) 2014-03-18
EP2771021B1 (en) 2018-08-29
WO2013063120A2 (en) 2013-05-02
HK1206616A1 (en) 2016-01-15
CN104321071A (zh) 2015-01-28
JP6210993B2 (ja) 2017-10-11
US20150315237A1 (en) 2015-11-05
RU2621049C2 (ru) 2017-05-31
RU2014121090A (ru) 2015-12-10
CN109232713A (zh) 2019-01-18
WO2013063120A3 (en) 2014-10-16
AU2019204073A1 (en) 2019-07-04
ES2703904T3 (es) 2019-03-13
US20130035292A1 (en) 2013-02-07
CA2853364C (en) 2019-12-24
KR101692275B1 (ko) 2017-01-04
US20180237474A1 (en) 2018-08-23
US20190135862A1 (en) 2019-05-09
JP2015505296A (ja) 2015-02-19
SG11201401776WA (en) 2014-10-30
US20160368947A1 (en) 2016-12-22
CA2853364A1 (en) 2013-05-02
US20150051262A1 (en) 2015-02-19
EP2771021A2 (en) 2014-09-03
KR102038161B1 (ko) 2019-10-29
AU2012328927A1 (en) 2014-05-15
AU2017213587A1 (en) 2017-08-31
EP2771021A4 (en) 2015-12-23
AU2012328927B2 (en) 2017-06-22
KR20120129954A (ko) 2012-11-28
AU2019204073B2 (en) 2020-07-23
BR112014009851A8 (pt) 2021-06-08
KR20140093245A (ko) 2014-07-25

Similar Documents

Publication Publication Date Title
BR112014009851A2 (pt) moduladores de receptor de nmda e usos dos mesmos
BRPI0918868B8 (pt) compostos moduladores do receptor de nmda e composições compreendendo os mesmos
SG10201805552PA (en) Sodium channel modulators for the treatment of pain and diabetes
BR112015018092A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
SG10201811584RA (en) Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
BR112015017997A8 (pt) amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112014031730A2 (pt) entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1
WO2011119227A3 (en) Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
MX2011008616A (es) Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
MX2015009778A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
MX356343B (es) Compuestos que inhiben la exocitosis neuronal (ii).
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
BR112016009443A8 (pt) moduladores do receptor de nmda, pró-drogas e seus sais
WO2013038200A3 (en) Neurodevelopmental disorders
UA112981C2 (uk) Варіант людського gdnf
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.